Li Huawen, Zhou Xia, Zhu Wenyan, Zhang Jing
South the Taihu Lake Hospital, Huzhou University, Department of Cardiology, Zhejiang Province, China.
Zhoushan Branch of the Affiliated Hospital of Shanghai Jiao Tong University School of Medicine, Department of Cardiology, Huzhou, China.
J Med Biochem. 2025 Aug 21;44(5):1003-1008. doi: 10.5937/jomb0-55833.
To analyse the effects of statins on the levels of sCD40, sCD146 and PAPP-An in patients with coronary heart disease (CHD).
126 patients with CHD treated from September 2022 to September 2024 were divided into a study group (n = 84) and a control group (n=42). The study group was randomly divided into groups A (n=42) and B (n=42). Patients in the control group were routinely treated with vasodilator, furosemide, digitalis and other cardiotonic agents. Based on routine treatment, patients in the study group were treated with Atto vastatin calcium tablets in group An and rosuvastatin calcium tablets in group B. Both groups were treated with 20 mg, oral administration before bedtime, and the treatment cycle was 3 months. The cardiac function grade, blood lipid level, serum sCD40, sCD146 and PAPP-A levels and adverse reactions were compared before and after treatment.
After treatment, the cardiac function of the three groups improved compared with that before treatment. The effect of patients in groups A and B was better than the control group. The blood lipid levels of the three groups were improved after treatment. The blood lipid levels of groups A and B were better than in the control group. The serum sCD40, sCD146, and PAPP-A levels between groups A and B were no different; after treatment, these in groups A and B were better than those in the control group. After treatment, there were some adverse reactions in all the three groups.
Statins effectively treat sCD40, sCD146, and PAPP-An in patients with CHD. They can significantly improve their cardiac function and blood lipid levels and effectively regulate sCD40, sCD146, and PAPP-An levels in patients with coronary heart disease.
分析他汀类药物对冠心病（CHD）患者可溶性CD40（sCD40）、可溶性CD146（sCD146）和妊娠相关血浆蛋白A（PAPP-A）水平的影响。
选取2022年9月至2024年9月接受治疗的126例冠心病患者，分为研究组（n = 84）和对照组（n = 42）。研究组随机分为A组（n = 42）和B组（n = 42）。对照组患者常规使用血管扩张剂、呋塞米、洋地黄等强心剂治疗。研究组患者在常规治疗基础上，A组使用阿托伐他汀钙片，B组使用瑞舒伐他汀钙片。两组均睡前口服20 mg，治疗周期为3个月。比较治疗前后两组患者的心功能分级、血脂水平、血清sCD40、sCD146和PAPP-A水平及不良反应。
治疗后，三组患者的心功能均较治疗前有所改善。A组和B组患者的治疗效果优于对照组。三组患者的血脂水平均有所改善。A组和B组的血脂水平优于对照组。A组和B组之间的血清sCD40、sCD146和PAPP-A水平无差异；治疗后，A组和B组的这些指标优于对照组。治疗后，三组均出现了一些不良反应。
他汀类药物可有效治疗冠心病患者的sCD40、sCD146和PAPP-A。它们可显著改善患者的心功能和血脂水平，并有效调节冠心病患者的sCD40、sCD146和PAPP-A水平。
